Sovaldi tablets 400 mg for hepatitis C (Sofosbuvir)

General information on Japanese Sovaldi tablets 400 mg from for hepatitis C (Sofosbuvir)    

Package details: 14 tablets

Manufacturer: Gilead Sciences K. K., Japan

Active ingredient: sofosbuvir (chemical formula C22H29FN3O9P)

Medical effect: Sovaldi tablets are effective for treatment of hepatitis C infection in patients with genotype 2 (serotype 2) and patients not belonging to genotype 1 or genotype 2 (e.g., patients with genotypes 3, 4, 5 or 6).

Contraindications and precautions: do not use in the following categories of patients:

• patients with renal dysfunction,
• patients with hepatitis B,
• patients with hepatitis B in history,
• pregnant or breastfeeding women.

Avoid taking any food containing St. John's wort while taking this medication. When used together with ribavirin, avoid pregnancy of your own or your partner during all the course of treatment and at least 6 months after it. If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration of Japanese Sovaldi tablets 400 mg for hepatitis C (Sofosbuvir)

1. For patients with serogroup 2 (genotype 2): take 1 tablet 1 time a day for 12 weeks.
2. For patients with neither serogroup 1 (genotype 1) nor serogroup 2 (genotype 2): take 1 tablet 1 time a day for 24 weeks.
3. Please note that this medicine is supposed to be used concomitantly with ribavirin.

How effective are Sovaldi tablets 400 mg from Japan for hepatitis C (Sofosbuvir)?

Sovaldi tablets contain sofosbuvir, a prodrug that transforms into active antiviral agent within the body, first discovered in 2007. It works by inhibiting a protein involved in hepatitis C virus replication and suppressing the proliferation of hepatitis C virus. Sovaldi tablets should be used together with ribavirin. Studies proved that sofosbuvir shows great efficacy, low side effects and a high barrier to resistance (Harmeet Kaur Bhatia, Harmanjit Singh et al. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. Journal of Pharmacology & Pharmacotherapeutics, 2014 Oct-Dec; 5(4): 278–284).

Who should use Sovaldi tablets 400 mg from Japan?

Sovaldi are effective for suppressing viremia in patients with genotype 2 hepatitis C and in patients with genotypes, not including 1 or 2 (e.g., genotypes 3, 4, 5 and 6). Compensated cirrhosis does not affect their efficacy. High barrier to resistance allows to use Sovaldi tablets for patients with hepatitis C who have experienced treatment failure with other medications. Sofosbuvir is generally well-tolerated but it should not be used in patients with a history of hepatitis B as it may reactivate the virus.